Cabaletta Bio Inc [CABA] stock is trading at $2.34, up 6.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CABA shares have gain 8.84% over the last week, with a monthly amount drifted -2.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI downgraded its rating to In-line on December 20, 2024, and dropped its price target to $6. On December 19, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $6 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $10 on October 10, 2024. Jefferies initiated its recommendation with a Buy and recommended $36 as its price target on February 05, 2024. William Blair started tracking with a Outperform rating for this stock on November 29, 2023, and assigned it a price target of $38. In a note dated October 24, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $40 on this stock.
Cabaletta Bio Inc [CABA] stock has fluctuated between $0.99 and $3.67 over the past year. Currently, Wall Street analysts expect the stock to reach $16.33 within the next 12 months. Cabaletta Bio Inc [NASDAQ: CABA] shares were valued at $2.34 at the most recent close of the market. An investor can expect a potential return of 597.86% based on the average CABA price forecast.
Analyzing the CABA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.84, Equity is -1.07 and Total Capital is -1.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Cabaletta Bio Inc’s Current Ratio is 3.60. In addition, the Quick Ratio stands at 3.60 and the Cash Ratio stands at 1.32.
Transactions by insiders
Recent insider trading involved Chang David J., Chief Medical Officer, that happened on Jan 21 ’26 when 8800.0 shares were purchased. President, Science & Tech., Binder Gwendolyn completed a deal on Jan 21 ’26 to buy 11312.0 shares. Meanwhile, Director Tomasello Shawn bought 22725.0 shares on Jan 21 ’26.
